n evolving ability to support vital organ system function during a period of otherwise lethal physiologic insufficiency changed the process of hospital care over the last half of the 20th century. Over a relatively short period, the development of techniques of positive pressure ventilation, hemodialysis, and invasive monitoring and cardiovascular support transformed life-threatening illness from a rapidly lethal event to a chronic state that was, potentially, survivable. The impact has been profound; for example, the mortality of abdominal trauma on the battlefield was virtually 100% before World War I but had fallen to 2% to 3% during the Arab-Israeli conflict in 1973 (1). Necrotizing pancreatitis was uniformly lethal in the early 20th century (2); today, the majority of patients survive. Advances in the support of vital organ function gave rise to intensive care units (ICUs) as dedicated geographic venues for the administration of these technologies (3) and spawned an entirely new specialtythat of intensive care medicine.
The cost of this progress has been considerable. The provision of critical care services consumes more than 1% of the gross national product of many countries of the developed world (4). Moreover, the very successes of this new discipline have created an entirely unprecedented spectrum of clinical problems, arising in the wake of the profound physiologic derangements of critical illness and the heroic interventions applied to reverse them. For example, the emergence of Gram-negative organisms as significant pathogens in hospitalized patients is a phenomenon of the last half of the 20th century (5), and their subsequent replacement by relatively avirulent organisms such as coagulase-negative Staphylococci, Candida, Pseudomonas, and the Enterococcus, is an even more recent development (6). The syndrome of acute lung injury known as acute respiratory distress syndrome was first described less than four decades ago (7), and the role of the mode of support in the syndrome's evolution has been appreciated only in the last few years (8). Similarly, septic shock became a describable entity (9) only after resuscitation and organ system support techniques were sufficiently effective that overwhelming infection ceased to be a rapidly lethal event and was transformed into a prolonged, but survivable, process.
The ICU made possible a spectrum of disorders that are characterized by their strong association with inflammation and described by their effects on the function of individual organ systems: the acute respiratory distress syndrome, acute renal failure, disseminated intravascular coagulation, septic shock, and stress gas-trointestinal bleeding, to name a few. Yet, as emphasized so compellingly by Baue (10) a quarter of a century ago, it is not simply that any one of these organ system derangements is the cause of all the others. Rather, all share common features that justify their consideration as manifestations of a common process-initially described as multiple organ failure (11) (12) (13) (14) , and more recently termed multiple organ dysfunction syndrome (MODS) (15).
MODS is widely considered to be the leading cause of morbidity and mortality for patients admitted to an ICU (16 -19). However, despite its immediate and infinitely recognizable manifestations in the critically ill patient, its characterization as a discrete syndrome with a common and measurable pathologic basis has ben problematic. First, patients admitted to an ICU frequently have some degree of preexisting physiologic impairment, so that it may be difficult to differentiate derangements that are acute and potentially reversible from those that are chronic and irreversible. Second, the spectrum of disorders that lead to ICU admission commonly includes diseases that cause direct organ injury, for example, pneumonia or trauma producing acute lung injury, or mesenteric vascular ischemia causing liver dysfunction. Finally, the challenge in characterizing organ dysfunction in biochemical terms has been not a lack of definable abnormalities, but a surfeit (Table 1) . Literally hundreds of biochemical and cellular abnormalities have been described in patients with MODS, and their very number has made it difficult, if not impossible, to define a single common underlying event or process as the pathogenic basis of the disorder. Indeed, it is not at all clear whether MODS is a single pathologic process with highly variable clinical expression or simply the limited phenotypic expression of a large number of pathologically divergent processes. This paper will review the more prominent theories about the pathogenesis of MODS, recognizing that the mechanisms that have been proposed are by no means exclusive and are often best viewed as differing perspectives on common pathologic processes.
Uncontrolled Infection
The first descriptions of the MODS emphasized its common association with occult or poorly controlled infection (9, 13, 20), frequently either peritonitis (14) or pneumonia (21). However, more recent reports indicate that infection, although common in patients with MODS, is not necessarily present (22) and frequently follows, rather than precedes, the development of the syndrome (6). Indeed, nosocomial infection may be better considered a manifestation of MODS than a cause of it. Characteristic infecting florae include opportunistic organisms of low intrinsic virulence (notably Candida, coagulase-negative Staphylococci, Pseudomonas, and Enterococci) (6), as well as species whose emergence reflects local environmental factors (notably Acinetobacter and Stenotrophomonas) or selective antimicrobial pressures (methicillinresistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and extended-spectrum ␤-lactamase-producing Gram-negative organisms). Indeed, the prevalence of infection with the former group of organisms is strongly associated with the severity of MODS (Fig. 1) (23) .
Microbial products such as endotoxin may also be a cause of MODS. Endotoxemia is much more common in the critically ill patient than is documented infection (24) and correlates poorly with culture-proven infection (25), suggesting an important role for the absorption of endotoxin from the gastrointestinal tract (26) or lung (27).
It is generally accepted that the morbidity of bacterial infection arises indirectly, through such downstream effects as the activation of an inflammatory response or the induction of intravascular coagulation in the host. However, bacterial products can be directly toxic to cells, altering fundamental cellular processes, as in the case of cholera toxin, or inducing the apoptosis, or programmed cell death, of neutrophils (28, 29) and epithelial cells (30).
Although infection commonly triggers MODS, the evidence that infection plays an important role in the evolution of the syndrome is not compelling. Metaanalyses of the effects of infection prophylaxis using the techniques of selective digestive tract decontamination show a striking reduction in rates of such infections as pneumonia, wound infection, and bacteremia but a much more modest, albeit statistically significant, reduction in mortality (31, 32). Moreover, peritonitis and pneumonia are frequent causes of MODS, but the evidence that successful treatment of either alters outcome is far from compelling (33-36). The pathogenic role of endotoxin is equally uncertain: Selective digestive tract decontamination, enteral feeding APC, activated protein C; G-CSF, granulocyte colony-stimulating factor; ICU, intensive care unit; IL, interleukin; PAF, platelet activating factor; TFPI, tissue factor pathway inhibitor; TNF, tumor necrosis factor. none of the dozen or more clinical trials that have evaluated endotoxin neutralization as a therapeutic strategy have shown unequivocal evidence of benefit, and at least one (37) raised the possibility that such an approach might be harmful.
Uncontrolled Systemic Inflammation
Clinical evidence of systemic inflammation is evident in almost all patients developing MODS (38 -40); in fact, remote organ dysfunction can be considered the functio laesa of systemic inflammation. Although it is difficult to differentiate the clinical manifestations of inflammation from the infections that are commonly their cause, it can be shown that the severity of the clinical inflammatory response, rather than the presence or absence of infection, is the more important determinant of ICU survival (39) (Fig. 2 ).
An extraordinary number of proinflammatory mediator molecules have been implicated in the expression and resultant morbidity of a systemic inflammatory response. The lethality of murine endotoxemia, for example, can be prevented by specific neutralization of more than two dozen inflammatory mediators, including interleukin (IL) 1, tumor necrosis factor (TNF), high mobility group 1, interferon ␥, leukemia inhibitory factor, macrophage migration inhibitory factor, IL-12, and phospholipase A 2 (41), although their neutralization has variable effects in other models. Cohort studies in critically ill patients show that increased circulating levels of cytokines such as TNF and IL-6 (42-44), or markers of increased release of TNF in response to inflammatory stimuli (45, 46) are associated with organ dysfunction and an increased risk of death.
Although the synthesis and release of a panoply of biochemical mediators of inflammation is characteristic of both experimental and clinical sepsis, the mechanisms through which these molecules may induce organ injury are much less clear. The cellular receptor for tumor necrosis factor is a member of the Fas family of death receptors that are capable of initiating apoptosis or programmed cell death in their cellular targets (47). However, the same receptor delivers an inflammatory and antiapoptotic signal to cells such as neutrophils, and the extent to which the effects of TNF reflect direct cellular injury is uncertain. TNF and other proinflammatory molecules can also activate downstream effectors of acute inflammation, for example, by upregulating the expression of inducible nitric oxide synthase (48), which results in increased release of nitric oxide and its attendant effects on microvascular resistance and capillary flow, or by augmenting neutrophil cytotoxic mechanisms by inducing the release of oxygen radicals and proteolytic enzymes (49, 50). Moreover, proinflammatory mediators can also up-regulate endothelial cell adhesion molecule expression (51) and activate endothelial procoagulant activity (52), while inhibiting the expression of thrombomodulin (53, 54), a critical factor in the activation of the protein C anticoagulant pathway.
An alternate model of the dysregulated inflammatory response that accompanies MODS suggests that the problem is not so much excessive inflammation as an acquired state of immunodeficiency or immune paralysis (55). The potential manifestations of this state of impaired immunity are many and include anergy to delayed hypersensitivity recall testing with common antigens (56), impaired de novo antibody synthesis to tetanus toxoid (57), reduced monocyte expression of human leukocyte antigen-DR (HLA-DR) (58), and increased circulating levels of counterinflammatory cytokines such as IL-10 (59) and transforming growth factor ␤ (60).
Clinical trials of a variety of strategies designed to inhibit inflammation in critical illness have generally yielded disappointing results, with pooled data from studies of the neutralization of TNF or IL-1 in sepsis showing a small but significant absolute mortality reduction of 3.5% to 5% (61). A recently completed, unpublished North American study of afelimomab, a monoclonal antibody to TNF, suggested that this mortality benefit can be increased if patients with an exaggerated inflammatory response reflected in elevated circulating levels of IL-6 are targeted and that neutralization of TNF also reduces the severity of organ dysfunction developing subsequent to the onset of treatment. However, the rela- Figure 1 . Association of nosocomial infection caused endemic intensive care unit pathogens with the severity of organ dysfunction, measured using a numeric score. Nosocomial infection is rare in patients without organ dysfunction; its prevalence increases in direct relation to the severity of multiple organ dysfunction syndrome (MODS), and its evolution follows the development of the syndrome, suggesting that nosocomial infection is a reflection, rather than a cause, of MODS. MOF, multiple organ failure. The differential impact of infection as a microbial phenomenon and sepsis as the response of the host was investigated in a study of 212 admissions to a surgical intensive care unit (ICU). Infection was diagnosed using objective microbiological and radiographic criteria, without reference to clinical manifestations. The severity of the septic response was graded using a sepsis score that quantifies abnormalities in five separate domains (temperature, white cell count, change in level of consciousness, cardiac output or systemic vascular resistance, and insulin requirements) on a 3-point scale. Scores were calculated daily; the maximum value was 15. Top, when patients meeting criteria for infection were evaluated, nonsurvivors had higher sepsis scores than survivors, whether in response to community-acquired or ICU-acquired infections. Bottom, in contrast, when patients with an activated septic response (a sepsis score of 7 or higher), no infection-related variable could be identified that discriminated survivors from nonsurvivors. Sepsis scores, however, remained higher in nonsurvivors. tively modest impact of such approaches suggests either that multiple redundant mediators must be targeted or that the ultimate morbidity of sepsis results from the downstream consequences of cytokine activity. The lack of efficacy of early high-dose corticosteroid therapy (62, 63) or ibuprofen (64), strategies that would be expected to reduce the levels of a number of inflammatory mediators, suggests that the latter interpretation may be more accurate.
Tissue Hypoxia
Reduced oxygen delivery or utilization would be expected to inhibit the normal physiologic functions of the cell; therefore, the assumption that cellular hypoxia is the final common pathway to organ dysfunction is attractive (65, 66) . Although adequate initial resuscitation usually restores oxygen delivery at the level of the whole organism, regional hypoxia in tissues such as the gastrointestinal tract (67, 68) or brain (69) is a well-documented phenomenon. Increased circulating concentrations of lactate are also suggestive of tissue hypoxia, either global or regional, and are associated with an adverse outcome (70, 71) .
Unfortunately, the initial enthusiasm for resuscitation to supranormal values to correct occult tissue hypoxia (72) has not been supported by more recent randomized trials (73) ; indeed, the use of transfusion (74) or large doses of dobutamine (75) to increase oxygen delivery actually worsens outcome and increases the severity of organ dysfunction. In the case of transfusion, at least, it appears that the deleterious effects arise from the failure of transfused red cells to reach the tissues, because of microvascular plugging by aged and poorly deformable red cells (76) . Alternatively, tissue hypoxia may result from derangements in the intracellular utilization of oxygen, in the face of adequate delivery, a pathologic state that has been termed "cytopathic hypoxia" (77) .
Dysregulated Apoptosis
Apoptosis describes a physiologic process through which cells activate an endogenous program that leads to the controlled death of the cell and its transformation to membrane-bound vesicles that are cleared by macrophages without evoking an inflammatory response (78) 
The expression of apoptosis is altered in critical illness. Apoptosis of lymphocytes and gut epithelial cells is increased (79, 80) , whereas that of neutrophils is delayed (81) (82) (83) . Excessive apoptosis has been implicated as a mechanism of liver (84) , kidney (85) , and cardiac (86) disease, and interventions that modulate the expression of apoptosis can improve outcome in a variety of experimental models of inflammation (87) . Intriguingly, the induction of apoptosis by Pseudomonas in tracheal epithelial cells (88) 
Microvascular Coagulopathy
The mechanisms that regulate the expression of inflammation are intimately linked to those that control the expression of coagulation, and multiple lines of evidence point to a pivotal role for inappropriate intravascular coagulation as a final common pathway to organ dysfunction. Cohort studies demonstrate a striking association between dysregulated coagulation and the development of organ dysfunction. In a longitudinal study of 136 patients who had sustained multiple trauma, Gando and colleagues (90) showed that early evidence of disseminated intravascular coagulation was a powerful predictor of subsequent organ dysfunction and that a platelet count of less than 80,000/ml had a sensitivity of 83.3% and a specificity of 100% for the prediction of MODS (90) .
The coagulopathy of critical illness is biologically complex and intertwined at multiple levels with the biological processes described earlier. Coagulation is initiated through tissue factor expressed on the surface of endothelial cells and monocytes, a process that can be induced by microbial products such as endotoxin (91) or cell surface components of Bacteroides fragilis (92) , by inflammatory cytokines (52, 93), or by integrin crosslinking (94) 
converts prothrombin to thrombin, which in turn results in the cleavage of fibrinogen to fibrin. Although fibrin deposition plays a critical role in hemostasis and in the localization of microorganisms within an abscess cavity, intravascular coagulation impedes oxygen delivery to tissues and can induce further inflammatory injury, indirectly through the response to hypoxia and directly through signals delivered to the thrombin receptor. Engagement of the thrombin receptor activates the nuclear transcription factor NFB (95), causing the transcription of a broad array of proinflammatory gene products and resulting in the release of nitric oxide (96) . Nor is the thrombin receptor unique as a mechanism through which an inflammatory response is amplified. Clustering of tissue factor has also been shown to initiate gene expression for proinflammatory cytokines, including TNF (97) .
Activation of coagulation is tonically inhibited by three major endogenous anticoagulant pathways. Antithrombin III is an inhibitor of serine proteases that inactivates a number of coagulation factors. It complexes with thrombin to form thrombin-antithrombin complexes and, through its binding to endothelium, initiates the release of prostacyclin, an inhibitor of platelet aggregation (98) . Tissue factor pathway inhibitor synthesized by endothelial cells inhibits factor Xa and the factor VIIa-tissue factor complex (99) . Finally, protein C is synthesized primarily in the liver, although extrahepatic synthesis occurs, particularly in the kidney and testis (100), and circulates as an inactive precursor. The protein C pathway is activated through the binding of thrombin to thrombomodulin on the endothelial surface, generating activated protein C, a serine protease that complexes with protein S to inhibit factors Va and VIIIa (101) .
The biology of protein C exemplifies the complex interactions between coagulation and inflammation that can amplify both and hence increase the resultant tissue injury. Protein C binds to a specific receptor on endothelial cells, the endothelial cell protein C receptor (EPCR), a process that amplifies the generation of activated protein C by thrombin-thrombomodulin complexes (102) . Inhibition of this interaction with a blocking antibody results in increased mortality, in association with an inflammatory cell infiltrate in the liver, kidneys, and adrenal glands, as well as elevated circulating levels of IL-6 and IL-8 (103). Proinflammatory cytokines such as TNF inhibit EPCR expression by augmenting EPCR's shedding from the endothelial cell surface and down-regulating its transcription (93) . Moreover ␣ 1 -antitrypsin, an acute-phase reactant, shortens the half-life of activated protein C (APC). Thus, APC interactions in vivo are predominantly antiinflammatory, whereas inflammation reduces APC levels and activity. As described earlier, the binding of thrombin to its receptor initiates NFB-dependent inflammatory gene transcription; in addition, thrombin up-regulates endothelial P selectin expression and induces synthesis of platelet-activating factor (104) . In addition to its role in the activation of protein C, thrombomodulin exhibits antiinflammatory properties; its administration to rats challenged with endotoxin prevented pulmonary leukosequestration and pulmonary vascular injury (105) .
Yet another example of the complex interactions between these physiologic processes is seen in the interactions between coagulation and programmed cell death. Phosphatidylserine is normally expressed asymmetrically on the inner aspect of the cell membrane. As part of the expression of apoptosis, phosphatidylserine becomes exteriorized and serves as one of the markers by which macrophages recognize and engulf apoptotic cells. However, exteriorized phosphatidylserine is also a potent stimulus for activation of the alternate pathway of complement and for induction of procoagulant activity leading to thrombin generation (106) .
Alterations in levels of factors that regulate the balance between coagulation and fibrinolysis are common in critically ill patients and cause a shift toward a procoagulant state (Table 2) . Changes in these parameters precede the development of organ dysfunction (107) and persist in those patients who develop organ dysfunction or die (108) . Moreover, protein C levels are decreased in acute renal failure, a discrete manifestation of MODS (109) , and in patients with neutropenia (110) .
A variety of strategies that target the coagulation cascade improve survival in experimental models (111) . In human volunteers, infusion of TNF activates coagulation and reproduces the coagulopathic profile of critical illness (112); paradoxically, neutralization of TNF may augment coagulation (113) . Early studies suggesting benefit for administration of antithrombin III (114, 115) were not replicated in a recent large phase III multicenter trial (S. Opal, unpublished observations). Recombinant tissue factor pathway inhibitor has shown promise in early-phase clinical studies, and a large multicenter phase III study is in progress. The administration of protein C has been shown to improve outcome in purpura fulminans (116) , and a phase II study of APC in sepsis showed a striking trend toward improved survival in a small cohort of patients (117) . The as yet unpublished results of a large phase III study of APC, terminated at an interim analysis because of impressive evidence of clinical efficacy (118) , should provide the most compelling evidence thus far that dysregulated coagulation is fundamental to the pathogenesis of MODS.
CONCLUSIONS
MODS is a prototypical exemplar of the application of complexity theory to an understanding of the pathophysiology of critical illness (119, 120) . It arises through the interactions of a network of physiologic insults including infection, the host inflammatory response, tissue ischemia, injury, and the interventions used to sustain organ function during a time of otherwise lethal insufficiency. Its mediators are many and interdependent, with the activity of one inducing the expression of others that amplify, inhibit, or otherwise modify the expression of the process. The clinical syndrome that emerges reflects the state of dynamic balance that exists between each of the component mediators and can be considered an emergent system.
The implications of an understanding of the complex nature of organ dysfunction are critical to the development of rational strategies to prevent or treat the process. Strategies directed against events early in the process may be effective as prophylaxis but are unlikely to have a significant effect on a process whose expression, at least from the perspective of the element targeted, has become autonomous. For example, although the prevention of infection in critical illness may reduce morbidity and mortality (121) , once such downstream events as proinflammatory mediator release have been activated, their persistence is not necessarily dependent on continuing infection. Similar consider- (122) , although the potential merits of targeting later circulating mediators such as high mobility group 1 (123) remain to be determined. In contrast, activation of coagulation is a relatively late consequence of the inflammatory response and, therefore, conceptually a more attractive therapeutic target.
In reality, the disparate biological processes that comprise inflammation are intimately interrelated, and strategies directed at one manifestation may have significant and unexpected consequences for others. Unfortunately, these processes are not demonstrated particularly well in small-animal models, and the elucidation of the richness of these interactions emerges only slowly, as data from trials of a variety of interventional strategies accumulate. The effects of ibuprofen on the physiology and survival of patients with sepsis: The
Question and Answer Session After Scientific Review
Benoit Vallet. You have indicated that activated protein C (APC) interferes primarily with coagulation rather than inflammation. Do you think this explains why APC therapy has succeeded in clinical trials, whereas anticytokine treatments, which target inflammation, have failed?
John Marshall. Absolutely. But I would disagree with the term "failure" to describe these trials. In many cases, the trial results were not truly negative, but inconclusive or suggestive of only marginal benefit. In addition, I am not arguing that coagulation is the be-all and end-all of the story. In fact, it may be that the final common pathway is related more to endocrine insufficiency rather than intravascular coagulopathy. At this stage, I think it is difficult to speculate on the extent to which coagulation is clinically important, nor am I sure that we can define a direct cytotoxic role for inflammation.
